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Abstract: Dome-shaped macula (DSM) was recently described in myopic patients as a convex 
protrusion of the macula within a posterior pole staphyloma. The pathogenesis of DSM and the 
development of associated serous foveal detachment (SFD) remain unclear. The obstruction 
of choroidal outflow and compressive changes of choroidal capillaries have been proposed as 
causative factors. In this paper, we report two cases of patients with chronic SFD associated 
with DSM treated with oral spironolactone. After treatment, there was a complete resolution of 
SFD in both patients. To the best of our knowledge, this is the first report of successful treatment 
of SFD in DSM by a mineralocorticoid receptor antagonist.
Keywords: serous foveal detachment, mineralocorticoid receptor antagonist, dome-shaped 
macula, treatment
Introduction
Dome-shaped macula (DSM) was recently described by Gaucher et al in myopic patients 
as a convex protrusion of the macula within a posterior pole staphyloma. DSM is associ-
ated more frequently with a high level of myopia or elevated eye axial length, but in 30% 
of cases, it is diagnosed in eyes with low refractive error.1 DSM can be complicated by 
serous foveal detachment (SFD), which usually produces a decrease in visual acuity 
and which is best diagnosed by high-resolution spectral-domain optical coherence 
tomography (SD-OCT). The prevalence of SFD in DSM is highly variable according to 
existing studies and fluctuates between 6% and 52%.1–4 In myopic eyes, the diagnosis of 
SFD complicating DSM can be challenging since it should be differentiated from other 
conditions associated with subretinal fluid (SRF) in the macular area, such as myopic 
choroidal neovascularization, idiopathic central serous chorioretinopathy, neovascular 
age-related macular degeneration, and polypoidal choroidal vasculopathy. The patho-
genesis of DSM and the mechanism leading to the development of SFD are still unclear. 
Whether treatment should be attempted to reduce SFD and which treatment should be 
proposed remain unknown. In the literature, one paper describes spontaneous resolution 
of SFD associated with DSM in one patient,5 and a second report describes a regression 
of SRF following half-fluence photodynamic therapy (PDT) in two patients.6
Herewith, we report two cases of SFD associated with DSM that were successfully 
treated with spironolactone. To the best of our knowledge, this is the first report of 
 efficient treatment of SFD in DSM by a mineralocorticoid receptor (MR) antagonist.
Patient 1
A 53-year-old Caucasian female patient was referred to our hospital for blurred 
central vision in her right eye. Over the past few weeks, she had noticed a decrease 
Correspondence: Francine Behar-Cohen
Jules Gonin eye Hospital, 15 avenue de 
France, Lausanne, switzerland
email francine.beharcohen@fa2.ch
Clinical Ophthalmology 2014:8submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
1000
Dirani et al
in vision and progressive metamorphopsia. Her past 
medical history was remarkable for scleroderma efficiently 
controlled by oral mycophenolate mofetil (1 g daily). 
Upon initial examination, her best-corrected visual acuity 
(BCVA) was 0.8 and 1.0 (decimal scale) in her right and 
left eyes, respectively. The patient had moderate myopia 
with a spherical equivalent of −3.25 D in both eyes. No 
significant findings were observed in the anterior segment 
or vitreous of either eye. Funduscopy showed bilateral tilted 
optic disc and bilateral inferonasal staphyloma with few 
foveal pigmentary changes in both eyes. In her right eye, 
fluorescein angiography and indocyanine green angiogra-
phy (HRA2; Heidelberg Engineering GmbH, Heidelberg, 
Germany) did not show evidence of choroidal neovascu-
larization (Figure 1A). SD-OCT (Spectralis; Heidelberg 
Engineering GmbH) showed a DSM in both eyes and SFD 
in the symptomatic right eye (Figure 1B). The patient was 
first treated with oral acetazolamide 250 mg three times 
daily but did not show any improvement after 2 months of 
therapy (Figure 1C). An intravitreous injection of 1.25 mg 
of bevacizumab (Avastin®; Genentech, South San Francisco, 
CA, USA) was performed 1 month later but BCVA and 
SD-OCT were unchanged. At 4 months after presentation, 
no improvement was noted; a course of oral spironolactone 
(Aldactone®; Pfizer, New York, NY, USA) was prescribed 
(75 mg once daily for 2 months) after giving a written informed 
consent for off-label use. Two months later, BCVA improved 
to 1.0 in the right eye, the metamorphopsia resolved, and the 
SFD that had been observed since the initial visit disappeared 
completely on SD-OCT (Figure 1D). The patient was 
 maintained on oral spironolactone and followed on a rou-
tine basis in our department with no recurrence of the SRF 
at 3 months post-resolution of SFD.
Patient 2
A 54-year-old Caucasian female patient who was followed 
in our hospital complained of distortions and deterioration of 
vision in her right eye that started 3 months prior to the initial 
examination. Upon examination, BCVA was 0.3 and 0.5 in the 
right and left eyes, respectively. The patient had undergone 
cataract surgery 2 years before the initial examination. Prior 
to surgery, she had bilateral high myopia with a spherical 
equivalent of −20 D and −23 D in her right and left eyes, 
respectively, that was reduced to −3 D. No significant find-
ings were observed in the anterior segment or vitreous of 
either eye. Fundoscopy showed bilateral posterior staphy-
loma with some macular pigmentary changes in both eyes. 
Fluorescein angiography and indocyanine green angiography 
(HRA2) of the right eye did not show evidence of choroi-
dal neovascularization (Figure 2A). SD-OCT (Spectralis) 
showed a DSM in both eyes with SFD only in the right eye 
(Figure 2B). The patient was treated with increasing doses of 
oral spironolactone (25 mg once daily for 1 week and 50 mg 
once daily thereafter) after giving a written informed consent 
for off-label use of spironolactone. Two months later, the 
BCVA improved to 0.4 in the right eye, the metamorphopsia 
Figure 1 Case 1: 53-year-old female patient.
Notes: (A) Late phase fluorescein angiography showing no sign of choroidal neovascularization or other causes of vascular leakage; (B) macular OCT of the right eye at 
presentation; (C) macular OCT after treatment with acetazolamide; (D) macular OCT after treatment with spironolactone. The green arrows indicate the level of the B-scan 
OCT sections.
Abbreviation: OCT, optical coherence tomography.
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Figure 2 Case 2: 54-year-old female patient.
Notes: (A) Late phase fluorescein angiography showing no sign of choroidal neovascularization or other causes of vascular leakage; (B) macular OCT of the right eye at 
presentation; (C) macular OCT after treatment with spironolactone. The green arrows indicate the level of the B-scan OCT sections.
Abbreviation: OCT, optical coherence tomography.
were reduced, and the SFD seen at the initial visit disappeared 
(Figure 2C). The patient was maintained on a low dose of 
oral spironolactone (25 mg once daily) for 6 months and was 
followed up for 1 year with no recurrence of the SFD.
Discussion
Several hypotheses have been advanced to explain the 
development of DSM, such as a resistance to deformation 
of scleral staphyloma,1 localized choroidal thickening in the 
macular area,1 ocular hypotony,7 scleral infolding through 
collapse of the posterior portion of the eye wall,7 and tan-
gential vitreoretinal traction.7 More recently, Imamura et al 
demonstrated that DSM may be the result of a localized 
relative thickness variation of the sclera under the macula 
in highly myopic patients.3
The pathogenesis of SRF accumulation in DSM also 
remains incompletely understood. Imamura et al suggested a 
fluid barrier mechanism caused by the thickened sclera, with 
severe obstruction in the outflow of choroidal fluid that may 
contribute to the development of SFD in DSM.3 Byeon and Chu 
proposed the term “scleral compression maculopathy”, where 
compressive changes of the choroid and choriocapillaris, and 
secondary retinal pigment epithelium alterations, may explain 
the development of SFD in DSM. These changes are character-
istically seen along the margin of the myopic staphyloma.8
According to Caillaux et al SFD is more common in 
patients with higher macular bulges and in vertically oriented 
oval-shaped domes.2 The choroidal thickness is signifi-
cantly greater (near normal) in the foveal area (on the top 
of the dome) than at the borders of the dome. However, the 
 relationship between macular choroidal thickness and SFD 
is not well understood.2
There are only a few published reports of  successful 
treatment of SFD associated with DSM. Two studies 
describe the unsuccessful use of argon laser photocoagulation 
for the treatment of SFD in DSM.1,9 According to a report 
by Chinskey and Johnson6 half-fluence verteporfin PDT 
( Visudyne®; Novartis AG, Basel, Switzerland) was employed in 
two patients with chronic SFD associated with DSM. 
Following a single treatment, SFD resolved completely in 
both cases with subjective improvement of visual symptoms. 
One patient had recurrence of submacular fluid 2 years later 
that responded incompletely to repeated half-fluence PDT 
treatment. Subsequent treatment with argon laser photocoag-
ulation led to complete resolution of SRF.6 In contrast, use of 
repeated intravitreal anti-vascular endothelial growth factor 
injections did not result in resolution of SFD associated with 
DSM, as reported by Chinskey and Johnson.6 Interestingly, 
Tamura et al reported a patient with bilateral SFD associated 
with DSM. The SFD resolved spontaneously in both eyes 
after 1 month. However, it recurred in one eye on the follow-
ing month and again, resolved spontaneously.5 Patients with 
SRF associated to DSM are relatively younger than patients 
with age-related maculopathy. They have a healthier retinal 
pigment epithelium and higher chance of spontaneous reso-
lution of SRF.
We have shown that MR antagonists are efficient 
for reducing SRF associated with central serous 
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chorioretinopathy.10,11 In the rat choroid, a potassium  channel 
(SK3) that belongs to the endothelial-derived relaxing factors, 
has been identified as a mineralocorticoid target involved in 
choroidal vasodilation.10 However, other mineralocorticoid 
molecular targets may contribute to the effect of spironolac-
tone, particularly in the retinal pigment epithelial cells, which 
express the MR.12 We therefore hypothesized that in addition 
to compressive and obstructive forces,  previously proposed 
as primum movens for the development of SFD, other 
mechanisms involving the mineralocorticoid pathway could 
be involved. Spironolactone is a well-known MR antagonist, 
used orally to treat many systemic diseases, and it does not 
expose to any potential choroidal occlusion unlike PDT. In 
the two patients presented herein, spironolactone seems to 
have had beneficial effects. Although additional randomized, 
controlled studies are needed to confirm the efficacy of this 
novel therapeutic approach of SFD associated with DSM, the 
risk/benefit ratio of oral spironolactone makes it an acceptable 
option for patients presenting non-resolving SRF associated 
with significant visual symptoms.
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